Palatin Technologies Inc (PTN) — Titan Protect Analysis

PTN

Palatin Technologies Inc

Healthcare · ·

$14.15

Data: 2026-06-03

✓ ETHICAL PASS

NONE MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$25M

Total market value of the company

Trailing P/E

126.00

Expensive — high growth expected

Forward P/E

-5.70

Based on estimated future earnings — lower means cheaper

Rev Growth

N/A

Year-over-year revenue change

Profit Margin

-48.5%

How much profit the company keeps from each dollar of revenue

ROE

-297.2%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$53.00

+275% from current price — median analyst estimate

Recommendation

NONE

Consensus view from 3 analysts covering this stock

About Palatin Technologies Inc

Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 MC4R agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity in Phase 2 trial, as well as Bremelanotide co-formulated with a PDE5i for the treatment of ED in patients not adequatel

https://palatin.com

Country: United States Employees: 29 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKDOWN

Price trending down — defensive positioning

Sharpe Ratio

0.201

Positive but modest risk-adjusted returns

Kelly Fraction

-0.0662

No positive edge detected — the data suggests staying out

Calmar Ratio

-0.645

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-62.0%

Historical annualised return based on price data

Max Drawdown

-96.1%

Largest peak-to-trough decline — the worst it has been

HMM State

BEAR

Statistical model detects bearish conditions

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

-0.09

Very low correlation to market moves

52W High

$31.00

54% below the year high

52W Low

$4.50

214% above the year low

Avg Volume

15,211

Average daily shares traded — higher means easier to buy and sell

Short Ratio

10.0

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$0.11

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

2.71

Heavy leverage — higher financial risk if revenues decline

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

4.3%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-40.3%

Profit from core operations before interest and tax

Free Cash Flow

N/A

Negative — the business is spending more than it generates

Revenue (TTM)

$13M

Total revenue over the last 12 months

Net Income

$-6,249,112

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$60.00

Target Median

$53.00

Target Low

$47.50

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go